The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.
May 28th 2024
Sanjal Desai, MD, discusses the feasibility of venetoclax rechallenge following progression on BTK inhibitors in chronic lymphocytic leukemia.
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Dr. Ferrajoli on the Benefits and Limitations of Frontline Fixed-Duration Therapy in CLL
September 15th 2023Alessandra Ferrajoli, MD, discusses the benefits and limitations of utilizing fixed-duration therapy with monoclonal antibodies in the frontline setting for patients with chronic lymphocytic leukemia.
Dr. Shadman on the Efficacy and Safety of Zanubrutinib in CLL
September 7th 2023Mazyar Shadman, MD, MPH, discusses the efficacy and safety of zanubrutinib in chronic lymphocytic leukemia, as well as data derived from the agents use which supports the regulatory approval of zanubrutinib in this patient population.
Pirtobrutinib, Liso-Cel Could Expand Treatment Arsenal for Relapsed/Refractory CLL
Mazyar Shadman, MD, MPH, discusses the evolution of BTK inhibitors in CLL, highlights how treatment patterns have evolved with the continued emergence of data on ibrutinib, acalabrutinib, and zanubrutinib, and expands on how pirtobrutinib and liso-cel could address unmet needs for this patient population.
Acalabrutinib Approved in China for Chronic Lymphocytic Leukemia
The National Medical Products Administration in China has approved acalabrutinib for use in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received at least 1 therapy.
Dr Islam on the Limited Use of Ibrutinib in CLL
September 1st 2023Prioty Islam, MD, MSc, discusses the current status of the first-generation BTK inhibitor ibrutinib following the FDA approvals of next-generation BTK inhibitors in patients with chronic lymphocytic leukemia and expands on the few instances in the clinic where she may lean toward treatment with ibrutinib instead of the next-generation BTK inhibitors zanubrutinib or acalabrutinib.
Evolving Drug Classes Expand Treatment Options Across Hematologic Malignancies
August 18th 2023Individualized myelofibrosis treatment begins with correctly identifying a patient’s disease subtype and considering their symptoms, from which accurate decisions regarding the use of JAK inhibitors vs radiation vs hypomethylating agents can lead to spleen and symptom burden reductions.
FDA Grants Clearance for Phase 3 Study of Lisaftoclax in Previously Treated CLL/SLL
The FDA has granted clearance for a global, registrational, phase 3 study examining lisaftoclax in combination with a BTK inhibitor in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who received prior treatment with a BTK inhibitor.
Earlier-Line Pirtobrutinib Investigation May Alter BTK Inhibitor Sequencing in CLL and MCL
August 1st 2023Prioty Islam, MD, MSc, discusses findings from the BRUIN trial, highlights the potential benefits of using noncovalent BTK inhibitors instead of or before covalent BTK inhibitors in patients with MCL or CLL, and previewed ongoing clinical trials investigating this class of agents in earlier treatment lines in these populations.
Fixed-Duration CAPTIVATE Regimen Is Effective in CLL Regardless of High-Risk Genomic Features
July 7th 2023Treatment with fixed-duration ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia in the first-line setting elicited durable responses and sustained progression-free survival outcomes regardless of high-risk genomic features.
Glofitamab Monotherapy Produces Sustained Responses in Richter Syndrome
July 6th 2023Administration of glofitamab after pretreatment with obinutuzumab provided encouraging antitumor activity with high and durable complete response rates and a manageable safety profile in heavily pretreated patients with Richter syndrome.
Leveraging BTK Inhibitors in Chronic Lymphocytic Leukemia
June 26th 2023The choice of BTK inhibitor regimen for patients with chronic lymphocytic leukemia must be tailored to the patient, taking into consideration their preferences and comorbidities, as well as potential treatment-related adverse effects.
Venetoclax/Atezolizumab/Obinutuzumab Elicits Durable Responses in Richter Transformation
The combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter transformation, according to data from the phase 2 MOLTO trial.
Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit in Treatment-Naïve CLL
June 22nd 2023Fixed-duration therapy with venetoclax plus obinutuzumab led to 60% reduction in the risk of progression or death compared with chlorambucil plus obinutuzumab, with benefit seen regardless of TP53 or IGHV mutation status, in previously untreated patients with chronic lymphocytic leukemia.
Zanubrutinib Plus Obinutuzumab and Venetoclax Induces High Undetectable MRD Rate in CLL/SLL
June 22nd 2023Zanubrutinib plus obinutuzumab and venetoclax demonstrated lasting responses characterized by sustained progression-free survival and undetectable minimal residual disease in peripheral blood and bone marrow in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Zanubrutinib Maintains PFS Benefit With Extended Follow-Up in Previously Untreated CLL/SLL
Extended follow-up from the phase 3 SEQUOIA trial demonstrated that zanubrutinib maintained a progression-free survival benefit compared with bendamustine plus rituximab in previously untreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Study Protocol Differences May Affect BTK Inhibitor Performance in R/R CLL
June 21st 2023Patients with relapsed/refractory chronic lymphocytic leukemia treated with ibrutinib in the phase 3 RESONATE trial achieved a significantly longer median progression-free survival compared with those in the phase 3 ALPINE trial, as well as a higher yet nonsignificant 2-year PFS estimate vs those in the phase 3 ELEVATE-RR trial.
Zanubrutinib, Liso-Cel Data Highlight the Evolving Treatment Landscape in CLL
Luke J. Mountjoy, DO, discusses the implications of the SEQUOIA and the ALPINE trial, the importance of coming up with feasible and effective treatment options for patients with 17p deletions and TP53 mutations, and the investigation of liso-cel in patients with relapsed/refractory CLL.
Phase 3 CLL12 Data Support Watch-and-Wait Approach in Early-Stage CLL
June 11th 2023Ibrutinib did not prolong survival vs placebo and is linked with increased susceptibility to bleeding in patients with asymptomatic early-stage chronic lymphocytic leukemia, suggesting that a watch-and-wait approach should continue as the standard for this population.
Venetoclax Plus Rituximab Provides Long-Term Survival Benefit in Relapsed/Refractory CLL
Treatment with fixed-duration venetoclax plus rituximab continued to show superior survival benefit vs bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia, according to 7-year follow up data from the phase 3 MURANO trial.